// App-Quantinova.ai

40 : HBcrAg, HBV‐RNA declines in A Phase 2a Study Evaluating the Multi‐dose Activity of ARB‐1467 in HBeAg‐Positive and Negative Virally Suppressed Subjects with Hepatitis B

Researchers

Presenter

  • Kosh Agarwal

Principal Investigators

  • Edward J. Gane

  • Wendy Cheng

  • William Sievert

  • Stuart K. Roberts

  • Sang Hoon Ahn

  • Yoon Jun Kim

  • Adrian Streinu-Cercel

  • Jill Denning

  • William Symonds

  • Patricia Mendez

Medical Centers

  • King's College Hosptial NHS Foundation Trust, London, United Kingdom

  • Auckland Clinical Studies Limited, Auckland, New Zealand

  • Royal Perth Hospital and Linear Research, Perth, WA, Australia

  • Monash Health, Melbourne, Australia

  • The Alfred Hospital, Melbourne, Australia

  • Inha University College of Medicine, Korea (Republic of)

  • Seoul National University College of Medicine, Seoul, Korea

  • Carol Davila University of Medicine and Pharmacy, National Institute for Infectious Diseases Prof. Dr. Matei Bals, Bucharest, Romania

  • Arbutus Biopharma, Inc, Burnaby, BC, Canada

Locations

  • United Kingdom

  • New Zealand

  • Australia

  • Republic of South Korea

  • Romania

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Hepatitis B

Biomarkers

  • Hepatitis B surface antigen

  • Hepatitis B e antigen

  • Serum hepatitis B virus DNA

  • Hepatitis B core-related antigen

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved